Biologics and Biosimilars Transport: Cold Chain Requirements and Transit Risk for Malaysian Importers

Biologics and biosimilars are the most demanding pharmaceutical segment in the import programme. They carry the highest per-kilogramme cargo value, the tightest temperature tolerances, the most restrictive stability data, the most documentation-heavy chain of custody, and the most expensive replacement cost when something goes wrong. They are also the segment most consistently underinsured by Malaysian importers, because the standard practice of declaring at invoice value misses the registration, testing, and replacement-supply costs that make biologic replacement materially more expensive than the bare commercial invoice.

This guide walks through what biologics and biosimilars are, the cold chain regimes they move under, the stability data that anchors the in-transit conditions, and the cargo insurance structure that closes the underinsurance gap. The primary technical references are IATA's Temperature Control Regulations (TCR), 14th Edition 2026, the WHO Good Distribution Practices for Pharmaceutical Products (Technical Report Series 957, Annex 5), and the NPRA Guideline on Good Distribution Practice (3rd Edition, 2018) with its Supplementary Notes on Time and Temperature Sensitive Products (TTSP).

Key Facts: Biologics and Biosimilars Transport for Malaysian Importers

What is a biologic? A biologic is a medicinal product whose active substance is produced by or extracted from a biological source, typically through recombinant DNA technology or cell culture. The category includes monoclonal antibodies, vaccines, blood products, insulin, recombinant therapeutic proteins, and increasingly cell and gene therapies (US FDA and EMA usage).

What is a biosimilar? A biosimilar is a biologic product that is highly similar to an already authorised reference biologic, with no clinically meaningful differences in safety, purity, or efficacy (US FDA and EMA definitions). The primary amino acid sequence must be identical to the reference product; other critical quality attributes, including glycosylation profile for monoclonal antibodies, must be matched within tightly specified tolerances.

What temperature ranges apply to biologic cold chain transport? Three temperature regimes dominate. Refrigerated cold chain (2°C to 8°C) covers the majority of finished dose biologics including most monoclonal antibodies, insulin, and many vaccines. Frozen (typically minus 20°C) covers certain biologics and vaccines. Ultra-low temperature (around minus 70°C to minus 80°C) covers mRNA vaccines, some cell and gene therapy products, and certain specialty biologics where stability data does not permit higher storage temperatures.

What does the stability data on the NPRA registration mean for in-transit conditions? Each registered biologic carries stability data submitted with the MAL registration application, defining the temperature range, the cumulative excursion tolerance, and the time-out-of-specification allowance. Stability data is product-specific and is more restrictive than the regime category alone suggests; a 2°C to 8°C biologic might tolerate a brief excursion to 25°C, or might require destruction on any excursion outside specification.

How are biologics typically transported into Malaysia? Most refrigerated biologics into Malaysia move on air freight under IATA CEIV Pharma certified handling, in active temperature-controlled unit load devices (ULDs) or passive qualified pallet shippers. A smaller proportion moves on reefer sea freight at 2°C to 8°C for biosimilars with adequate stability data and lower per-shipment urgency. Ultra-low temperature biologics travel almost exclusively on air freight with dry ice (sublimation point minus 78.5°C, classified as dangerous goods under IATA DGR UN 1845) or with specialised vapour-phase liquid nitrogen systems.

Where does the underinsurance trap sit on biologics? Standard practice declares biologics at invoice value plus the 10 percent uplift under UCP 600 Article 28. This misses the NPRA registration costs, the stability testing costs, and the replacement lead time costs that materially increase the true replacement cost above invoice value. The underinsurance trap surfaces at claim, where the declared value caps the recovery below the actual loss to the business.

For the related coverage frameworks, see the pharmaceutical imports cargo insurance cluster hub, Institute Cargo Clauses, and the Pharmaceutical & Medical Devices Cargo Insurance industry page.

Resource: Cargo Insurance Coverage Audit

Take the 9-question Cargo Insurance Coverage Audit to score your biologic and biosimilar cargo cover against the replacement-cost valuation and ultra-low temperature baseline. Free, no signup wall.

What Biologics and Biosimilars Are

The clearest definitional anchor sits with the US FDA and the European Medicines Agency, which use materially aligned approaches to biologic and biosimilar approval.

A biologic is a medicinal product whose active substance is biological in origin, typically produced through recombinant DNA technology or extracted from biological sources. The category covers a wide range of product classes including monoclonal antibodies, vaccines, blood and plasma products, insulin and other peptide hormones, recombinant therapeutic proteins (interferons, growth hormone, erythropoietin), and the newer cell and gene therapy products.

A biosimilar is a biologic product approved on the basis of a comparability exercise demonstrating high similarity to an already authorised reference biologic, with no clinically meaningful differences in safety, purity, and efficacy. The biosimilar's primary amino acid sequence must be identical to the reference product. Other critical quality attributes, including aggregate levels, bioactivity, charge heterogeneity, and the glycosylation profile (particularly important for monoclonal antibodies where glycosylation may form part of the mechanism of action), must match the reference within tightly specified tolerances.

From a cargo insurance perspective, biologics and biosimilars present substantially the same cold chain profile. The economic considerations differ (biosimilars typically command a lower price than the originator biologic), but the stability data, the cold chain regime, the documentation requirements, and the per-kilogramme transit risk are broadly comparable. Both segments require the same depth of placement attention.

The Three Temperature Regimes That Govern Biologic Transit

Biologic transit operates under three temperature regimes, each with its own technology stack and documentation expectations.

Most refrigerated biologic transport (the largest category by volume of finished-dose biologic imports into Malaysia) sits at 2°C to 8°C. The 2°C lower bound is as important as the 8°C upper bound: many liquid biologic preparations cannot tolerate accidental freezing, and a product that freezes and thaws is typically not fit for use even if the post-thaw appearance is unchanged. Both excursion directions (above 8°C and below 2°C) need to be monitored and documented.

For biologic and biosimilar importers, Specialist High-Value Transit Insurance is the working placement structure where per-shipment values exceed standard open cover limits; for ongoing programmes, Marine Cargo Open Cover with replacement-cost valuation and temperature deviation endorsements applies. For the industry view, see Pharmaceutical & Medical Devices Cargo Insurance.

Ultra-low temperature transit is the most operationally demanding regime. Dry ice (solid carbon dioxide, sublimation point minus 78.5°C at atmospheric pressure) is the most common cooling medium. Dry ice is classified as dangerous goods under IATA Dangerous Goods Regulations (UN 1845), with quantity limits per aircraft consignment. Documented stability studies have identified pH changes in certain biologic formulations exposed to dry ice in specific container materials, which is a packaging design consideration rather than a temperature consideration.

Stability Data: The Often-Overlooked Anchor

The single most important document for biologic transit is the product's stability data, submitted with the MAL registration application to the Drug Control Authority. Stability data defines, for each registered product:

• The acceptable temperature range for storage.
• The maximum cumulative excursion permitted before the product is treated as out of specification.
• The time-temperature relationship (some products tolerate brief excursions at moderate ambient; some require destruction on any excursion).
• The labelled storage condition (typically "store between 2°C and 8°C", with or without permitted excursion language such as "excursions up to 25°C permitted for 24 hours").

The labelled storage condition on the product packaging is a summary of the underlying stability data. The actual stability profile, including the cumulative excursion tolerance, is documented in the MAL registration dossier and is the basis on which the importer's quality team would make a decision about whether a product remains fit for use after a documented excursion event.

For cargo insurance purposes, the stability data drives two practical points. First, the temperature deviation endorsement on the policy should specify the temperature range that matches the registered product's stability, not a generic "2°C to 8°C" specification that may be more permissive than the actual product allows. Second, the excursion trigger (combination of time and degrees) on the endorsement should match what the stability data treats as breach.

The Documentation Pack for a Biologic Consignment

A biologic consignment requires a more extensive documentation pack than general pharmaceutical product. The standard set includes:

• The MAL registration certificate confirming the product is registered in Malaysia.
• The current NPRA Import Licence with the biologic on the listed annex.
• The product's stability data summary as relevant to the in-transit conditions.
• Pre-shipment temperature validation and qualification of the packaging used for the consignment.
• Continuous temperature logger data from origin to destination, with no gaps, calibrated to the registered product's stability range.
• Chain-of-custody handover records at every transshipment, signed by both the releasing and receiving party.
• The transport document (airway bill for air freight, sea bill of lading for reefer sea freight).
• The cargo insurance certificate with cover scope matching the biologic profile (see the broader LC Insurance Certificate Requirements framework for LC-funded biologic imports).
• Where the consignment is at ultra-low temperature using dry ice, the IATA Dangerous Goods Declaration for UN 1845.
• Post-delivery temperature verification at the GDP-certified Malaysian warehouse.
• Any deviation reports and corrective action documentation if an excursion is recorded during transit.

The Underinsurance Trap: Why Invoice Value Is Not Enough

This is the area where the largest commercial gap on biologic shipments most consistently surfaces, and the area that most often catches importer-distributors at claim.

Standard practice on cargo insurance valuation declares the consignment at CIF or CIP value plus a 10 percent uplift, following UCP 600 Article 28 for Letter of Credit transactions and broadly the same convention for non-LC pharmaceutical placements. For commodity pharmaceutical product (generics, OTC products, APIs), CIF plus 10 percent is generally a reasonable approximation of the importer's commercial exposure.

For biologics, it is not. The replacement cost of a biologic consignment includes the following elements beyond the bare commercial invoice:

The cumulative effect of the additional elements above can take true replacement cost meaningfully above CIF plus 10 percent. The practical fix is to negotiate the insured value basis with the underwriter at placement, with explicit reference to the replacement cost components rather than treating the standard 10 percent uplift as automatically sufficient. For biologics specifically, an uplift in the 15 to 25 percent range over CIF or CIP is more common in specialist placements, with the exact figure agreed against the importer's specific cargo profile.

The Cargo Insurance Structure for Biologic Imports

The cargo insurance placement for biologic imports into Malaysia is the most endorsement-heavy placement in the cluster. The named elements typically required are:

• Institute Cargo Clauses (A) 2009 as the all-risks base cover, with the air and sea scope explicit in the wording.
• Temperature deviation endorsement with the temperature range and excursion trigger aligned to the registered product stability data, not a generic specification.
• Reefer equipment breakdown extension where any portion of the programme moves on reefer sea freight.
• Montreal Convention gap cover where the air freight per-kilogramme cargo value exceeds the 26 SDR per kilogramme carrier liability cap (which it almost always does for biologics).
• Ultra-low temperature endorsement where dry ice or vapour-phase liquid nitrogen is used, including the IATA Dangerous Goods Regulations UN 1845 dimension.
• Replacement cost basis with the insured value agreed at full replacement cost (including registration, stability re-testing, and replacement lead time) rather than at invoice value alone.
• Institute War Clauses (Cargo) CL385 dated 01.01.2009 where the routing transits Joint War Committee listed areas (Persian Gulf, Red Sea and Bab-el-Mandeb, Black Sea as of May 2026).
• Institute Strikes Clauses (Cargo) CL386 dated 01.01.2009 with attention to delay exposure where the biologic has a limited shelf life.

For high-value biologic consignments where per-shipment value exceeds standard open cover marine cargo insurance per-shipment limits, see specialist and high-value transit insurance. For one-off ultra-low temperature biologic movements, see single shipment marine cargo insurance.

Biologics declared at invoice value are routinely underinsured.

Voyage arranges specialist marine cargo insurance for NPRA-licensed pharmaceutical importers with the insured value basis agreed at full replacement cost, not invoice value. Request a coverage review at voyagecover.com/#contact-form or WhatsApp Kevin at +60 19 990 2450.

Operational Risk Concentrations for Biologic Imports

Beyond the headline cold chain regime, three operational risk concentrations recur on biologic transit into Malaysia.

Transshipment dwell. Air freight transshipment hubs between origin (typically EU or US) and Malaysia frequently introduce ground handling time on the apron, where ambient temperature exposure is highest. The risk is more pronounced at tropical transshipment points than at temperate ones, but applies across the network. For Malaysian importers receiving biologics via KLIA, the ground handling time between aircraft and the airside cold storage facility is the most documented in-transit excursion exposure.

Customs clearance for biologic-classified imports. Pharmaceutical clearance at Malaysian entry points typically involves both Royal Malaysian Customs (JKDM) and NPRA verification stages. Biologic consignments at refrigerated or frozen temperatures need to remain in temperature-controlled storage throughout the clearance window. The Cold Chain Facilities List published by NPRA identifies premises assessed as suitable for cold chain handling; clearance facilities and bonded warehouses on the list are appropriate intermediate holding points.

Last-mile delivery to the GDP-certified warehouse. The final segment from KLIA cargo terminal or Port Klang reefer yard to the importer's GDP-certified Malaysian warehouse is operationally the shortest leg but is often where the cold chain documentation breaks down. The GDP supplementary notes on TTSP require temperature-controlled trucks and continuous monitoring through the last mile, with the chain-of-custody handover recorded at receipt.

Frequently Asked Questions

What is the difference between a biologic and a biosimilar?

A biologic is a medicinal product whose active substance is produced by or extracted from a biological source. A biosimilar is a biologic that has been approved on the basis of a comparability exercise demonstrating high similarity to an already authorised reference biologic, with no clinically meaningful differences in safety, purity, or efficacy. Both are regulated as biologics for product registration purposes and both share the same cold chain transport profile.

What temperature ranges are typical for biologic cold chain transport?

Refrigerated cold chain at 2°C to 8°C covers most monoclonal antibody therapies, insulins, and many vaccines. Frozen at around minus 20°C covers certain biologics and frozen vaccines. Ultra-low temperature at around minus 70°C to minus 80°C covers mRNA vaccines, some cell and gene therapy products, and certain specialty biologics. Each product's specific stability data anchors the in-transit conditions.

What stops me from declaring biologics at invoice value for cargo insurance?

Nothing stops you mechanically, but it leaves the policy underinsured. Biologic replacement cost includes NPRA registration costs, stability re-testing on replacement, replacement lead time costs, and freight at higher pharmaceutical rates. These elements are not captured in CIF or CIP value plus a 10 percent uplift. The practical fix is to agree an uplift in the 15 to 25 percent range over CIF or CIP value with the underwriter at placement, with explicit reference to the replacement cost components.

How does ultra-low temperature transport with dry ice work for biologics?

Dry ice (solid carbon dioxide, sublimation point minus 78.5°C at atmospheric pressure) is loaded into specialised passive shippers around the biologic product. As ambient heat enters the shipper, the dry ice sublimes from solid to gas, absorbing energy in the phase change and maintaining the internal temperature near minus 78°C. Dry ice is classified as dangerous goods under IATA Dangerous Goods Regulations UN 1845, with aircraft loading limits per consignment, so the air carrier's dry ice acceptance limits are part of the operational planning.

Can biologics be transported by sea reefer rather than air freight?

Yes, where the biologic's stability data supports the longer transit time. Standard reefer containers operate down to around minus 30°C and Super Freezer or equivalent units extend to around minus 60°C, which covers most refrigerated and conventional frozen biologics. Ultra-low temperature biologics (minus 70°C and below) are generally not transported on commercial sea reefer; dry ice air freight or specialised passive systems remain the practical option.

What IATA framework applies to biologic air freight?

IATA's Temperature Control Regulations (TCR), 14th Edition 2026, is the operational standard for temperature-controlled healthcare cargo by air. The IATA CEIV Pharma certification programme certifies airlines, ground handlers, forwarders, and trucking companies against pharmaceutical handling standards, with certification valid for three years. For biologic imports specifically, CEIV Pharma certification of the air freight chain is one of the principal risk reduction levers.

How does the Montreal Convention liability cap affect biologic air freight?

Montreal Convention 1999 caps carrier liability at 26 SDR per kilogramme of gross weight, effective 28 December 2024 under the ICAO five-year inflation review (approximately $35 per kilogramme at April 2026 rates). For biologics where per-kilogramme cargo value typically far exceeds the cap (high-value monoclonal antibodies and specialty oncology biologics can carry per-kilogramme values orders of magnitude above $35), the cargo insurance gap is the primary recovery route on losses.

Is reefer container equipment breakdown covered under standard ICC (A) for biologics?

Not by default. Equipment failure causing temperature excursion typically falls outside the ICC (A) 2009 base wording unless a reefer equipment breakdown extension is written into the policy. For biologics on reefer sea freight, the equipment breakdown extension is one of the foundational endorsements that the placement should address.

Voyage Conclusion

Biologics and biosimilars are the highest-stakes segment of the pharmaceutical import programme into Malaysia. They run on three cold chain regimes (refrigerated 2°C to 8°C, frozen around minus 20°C, ultra-low around minus 70°C to minus 80°C), they require the most documentation-heavy chain of custody, and they expose the importer to the largest gap between invoice value and replacement cost. The underinsurance trap on biologics is the most consistently encountered commercial gap in the cluster.

Talk to Voyage about Specialist High-Value Transit Insurance for biologic and biosimilar distributors, with replacement-cost valuation and temperature deviation endorsements negotiated at placement. For ongoing programmes, Marine Cargo Open Cover applies. For the industry view, see Pharmaceutical & Medical Devices Cargo Insurance. WhatsApp +60 19 990 2450 or use the contact form.

Take the Cargo Insurance Coverage Audit

Score your pharmaceutical cargo programme: Cargo Insurance Coverage Audit. Free, no signup wall.

Related in the pharmaceutical cluster: pharmaceutical imports cargo insurance cluster hub, importing controlled drugs into Malaysia, air freight pharmaceutical cargo insurance, plus the broader foundational guides: Institute Cargo Clauses and LC insurance certificate requirements.

Disclaimer: This article provides general guidance on biologics and biosimilars cold chain transport for pharmaceutical imports into Malaysia as of May 2026. Industry frameworks (IATA TCR, IATA CEIV Pharma, WHO GDP, NPRA GDP), product stability data, and route conditions are product-specific and may change.

Coverage terms, conditions, and availability vary by insurer, policy, and jurisdiction. Always review your specific policy wording and consult a qualified insurance or legal professional before making coverage decisions.